Efficacy and safety of pomalidomide as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma patients refractory to a lenalidomide-containing combination regimen

Authors :: Roy Mackintosh
Nashat Y. Gabrail
Haresh S. Jhangiani
Robert Vescio
Alberto Bessudo
Ashkan Lashkari
James R. Berenson
Tanya M. Spektor
Michael Oren Robinson
Tina Maluso
Regina A. Swift
Samir V. Kubba
Jeffrey D. Neidhart
Alexa Cohen
Ibrahim Nakhoul
Source :: Journal of Clinical Oncology. 36:e20012-e20012
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: e20012Background: Pomalidomide (POM) is a third–generation immunomodulatory drug shown to be safe and effective for the treatment of relapsed/refractory multiple myeloma (RRMM) patients (pts) previ...

Full Text Access

Tools